Pradaxa, Xarelto, and Eliquis are all members of a relatively new class of drugs known as new oral anticoagulants (NOACs). These drugs were designed for patients who suffer from a medical condition known as atrial fibrillation (Afib). Afib patients need a blood thinning medication to prevent deep vein clots from forming.
A deep vein clot can form a serous medical condition known as Deep Vein Thrombosis (DVT), where the clot forms in the veins of the legs and then breaks loose and travels though the blood system, where it can do serious damage. If the clot blocks the flow of blood to the brain, the patient will suffer a stroke, which can result in permanent injury or death. If the clot enters the lungs, it can puncture the pleural membrane, causing a serious internal bleeding condition known as a pulmonary embolism (PE). Continue reading
Product Liability Lawyer Blog











